Douglas E Rehder

US Patent:

7928205, Apr 19, 2011

Filed:

Oct 21, 2005

Appl. No.:

11/255528

Inventors:

Thomas M. Dillon - Ventura CA, US
Douglas Rehder - Phoenix AZ, US
Pavel Bondarenko - Thousand Oaks CA, US
Margaret Ricci - Camarillo CA, US
Himanshu S. Gadgil - Seattle WA, US
Douglas D. Banks - Bainbridge Island WA, US
Joe Zhou - Shanghai, CN
Yuefeng Lu - Newbury Park CA, US
Andrew Goetze - Newbury Park CA, US
Yuling Zhang - Redmond WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 39/395
C07K 16/00

US Classification:

5303905, 4241771, 435 696, 530408

Abstract:

The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.

US Patent:

20170010278, Jan 12, 2017

Filed:

Feb 11, 2015

Appl. No.:

15/119676

Inventors:

- Scottsdale AZ, US
Matthew Schaab - Phoenix AZ, US
Douglas Rehder - Phoenix AZ, US

Assignee:

Arizona Board of Regents on behalf of Arizona State University - Scottsdale AZ

International Classification:

G01N 33/68

Abstract:

Methods for quantifying biospecimen sample integrity using markers of oxidation (FIG. ). Under conditions of incomplete blood plasma/serum (P IS) sample freezing (including storage at −20 ?C), two different forms of oxidation occur spontaneously at protein sulfur atoms—namely S-cysteinylation of free cysteine residues (in which the oxidative event is disulfide bond formation) and sulfoxidation of methionine. Oxidized forms of albumin and apoA-1, SCA and MOA1 are useful markers of biospecimen integrity. The oxidative chemistries of SCA and MOAI are operational in other proteins and polypeptides. Thus, for rare cases in which the use of SCA or MOA1 may be contraindicated, custom designed surrogate peptide probes based on SCA and MOA1 oxidation chemistry may be fortified into samples at collection to serve as exogenous markers of P/S sample integrity.

US Patent:

20150376679, Dec 31, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/394021

Inventors:

- Scottsdale AZ, US
Douglas Rehder - Phoenix AZ, US

International Classification:

C12Q 1/48

Abstract:

The present disclosure provides a method for analyzing glycan-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.